FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2165416097> ?p ?o ?g. }

• W2165416097 endingPage "R53" @default.
• W2165416097 startingPage "R53" @default.
• W2165416097 abstract "We assessed the profile and frequency of malignancy subtypes in a large single-centre UK cohort for patients with scleroderma (systemic sclerosis; SSc). We evaluated the cancer risk among SSc patients with different antibody reactivities and explored the temporal association of cancer with the duration between SSc onset and cancer diagnosis.We conducted a retrospective study of a well-characterised cohort of SSc patients attending a large tertiary referral centre, with clinical data collected from our clinical database and by review of patient records. We evaluated development of all cancers in this cohort, and comparison was assessed with the SSc cohort without cancer. The effect of demographics and clinical details, including antibody reactivities, were explored to find associations relevant to the risk for development of cancer in SSc patients.Among 2,177 patients with SSc, 7.1% had a history of cancer, 26% were positive for anticentromere antibodies (ACAs), 18.2% were positive for anti-Scl-70 antibodies and 26.6% were positive for anti-RNA polymerase III (anti-RNAP) antibody. The major malignancy cancer subtypes were breast (42.2%), haematological (12.3%), gastrointestinal (11.0%) and gynaecological (11.0%). The frequency of cancers among patients with RNAP (14.2%) was significantly increased compared with those with anti-Scl-70 antibodies (6.3%) and ACAs (6.8%) (P < 0.0001 and P < 0.001, respectively). Among the patients, who were diagnosed with cancer within 36 months of the clinical onset of SSc, there were more patients with RNAP (55.3%) than those with other autoantibody specificities (ACA = 23.5%, P < 0.008; and anti-Scl-70 antibodies = 13.6%, P < 0.002, respectively). Breast cancers were temporally associated with onset of SSc among patients with anti-RNAP, and SSc patients with anti-RNAP had a twofold increased hazard ratio for cancers compared to patients with ACAs (P < 0.0001).Our study independently confirms, in what is to the best of our knowledge the largest population examined to date, that there is an association with cancer among SSc patients with anti-RNAP antibodies in close temporal relationship to onset of SSc, which supports the paraneoplastic phenomenon in this subset of SSc cases. An index of cautious suspicion should be maintained in these cases, and investigations for underlying malignancy should be considered when clinically appropriate." @default.
• W2165416097 created "2016-06-24" @default.
• W2165416097 creator A5000610272 @default.
• W2165416097 creator A5008098676 @default.
• W2165416097 creator A5009981315 @default.
• W2165416097 creator A5038984237 @default.
• W2165416097 creator A5063621671 @default.
• W2165416097 creator A5069180045 @default.
• W2165416097 creator A5080929229 @default.
• W2165416097 date "2014-01-01" @default.
• W2165416097 modified "2023-10-07" @default.
• W2165416097 title "Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma" @default.
• W2165416097 cites W1988241269 @default.
• W2165416097 cites W1996339094 @default.
• W2165416097 cites W2002342342 @default.
• W2165416097 cites W2013359460 @default.
• W2165416097 cites W2013900075 @default.
• W2165416097 cites W2018915293 @default.
• W2165416097 cites W2020568015 @default.
• W2165416097 cites W2022513732 @default.
• W2165416097 cites W2023946136 @default.
• W2165416097 cites W2024346357 @default.
• W2165416097 cites W2028921539 @default.
• W2165416097 cites W2039556556 @default.
• W2165416097 cites W2039908361 @default.
• W2165416097 cites W2041691065 @default.
• W2165416097 cites W2042860481 @default.
• W2165416097 cites W2062392118 @default.
• W2165416097 cites W2063392174 @default.
• W2165416097 cites W2066973023 @default.
• W2165416097 cites W2071216920 @default.
• W2165416097 cites W2073573977 @default.
• W2165416097 cites W2076282684 @default.
• W2165416097 cites W2076796605 @default.
• W2165416097 cites W2086326784 @default.
• W2165416097 cites W2091926291 @default.
• W2165416097 cites W2104145276 @default.
• W2165416097 cites W2105420339 @default.
• W2165416097 cites W2113150329 @default.
• W2165416097 cites W2121599003 @default.
• W2165416097 cites W2140816451 @default.
• W2165416097 cites W2143856183 @default.
• W2165416097 cites W2147909808 @default.
• W2165416097 cites W2154539652 @default.
• W2165416097 cites W2161082940 @default.
• W2165416097 cites W2161451618 @default.
• W2165416097 cites W2165911231 @default.
• W2165416097 cites W2171558254 @default.
• W2165416097 cites W4069880 @default.
• W2165416097 doi "https://doi.org/10.1186/ar4486" @default.
• W2165416097 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3978927" @default.
• W2165416097 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24524733" @default.
• W2165416097 hasPublicationYear "2014" @default.
• W2165416097 type Work @default.
• W2165416097 sameAs 2165416097 @default.
• W2165416097 citedByCount "146" @default.
• W2165416097 countsByYear W21654160972014 @default.
• W2165416097 countsByYear W21654160972015 @default.
• W2165416097 countsByYear W21654160972016 @default.
• W2165416097 countsByYear W21654160972017 @default.
• W2165416097 countsByYear W21654160972018 @default.
• W2165416097 countsByYear W21654160972019 @default.
• W2165416097 countsByYear W21654160972020 @default.
• W2165416097 countsByYear W21654160972021 @default.
• W2165416097 countsByYear W21654160972022 @default.
• W2165416097 countsByYear W21654160972023 @default.
• W2165416097 crossrefType "journal-article" @default.
• W2165416097 hasAuthorship W2165416097A5000610272 @default.
• W2165416097 hasAuthorship W2165416097A5008098676 @default.
• W2165416097 hasAuthorship W2165416097A5009981315 @default.
• W2165416097 hasAuthorship W2165416097A5038984237 @default.
• W2165416097 hasAuthorship W2165416097A5063621671 @default.
• W2165416097 hasAuthorship W2165416097A5069180045 @default.
• W2165416097 hasAuthorship W2165416097A5080929229 @default.
• W2165416097 hasBestOaLocation W21654160971 @default.
• W2165416097 hasConcept C121608353 @default.
• W2165416097 hasConcept C126322002 @default.
• W2165416097 hasConcept C143998085 @default.
• W2165416097 hasConcept C159654299 @default.
• W2165416097 hasConcept C163764329 @default.
• W2165416097 hasConcept C167135981 @default.
• W2165416097 hasConcept C180032290 @default.
• W2165416097 hasConcept C198451711 @default.
• W2165416097 hasConcept C203014093 @default.
• W2165416097 hasConcept C2779399171 @default.
• W2165416097 hasConcept C2779967694 @default.
• W2165416097 hasConcept C530470458 @default.
• W2165416097 hasConcept C71924100 @default.
• W2165416097 hasConcept C72563966 @default.
• W2165416097 hasConcept C90924648 @default.
• W2165416097 hasConceptScore W2165416097C121608353 @default.
• W2165416097 hasConceptScore W2165416097C126322002 @default.
• W2165416097 hasConceptScore W2165416097C143998085 @default.
• W2165416097 hasConceptScore W2165416097C159654299 @default.
• W2165416097 hasConceptScore W2165416097C163764329 @default.
• W2165416097 hasConceptScore W2165416097C167135981 @default.
• W2165416097 hasConceptScore W2165416097C180032290 @default.
• W2165416097 hasConceptScore W2165416097C198451711 @default.

• next